Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Flupirtine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 known ✓ | O43526 | 9/20 | 0.92 |
| ▸ | KCNQ3 known ✓ | O43525 | 7/20 | 0.92 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.92 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.92 |
| ▸ | KCNQ4 known ✓ | P56696 | 6/20 | 0.61 |
| ▸ | KCNQ5 known ✓ | Q9NR82 | 5/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.92 |
| ▸ | ESR1 | P03372 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | HTR1A | P08908 | 1/20 | 0.92 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.92 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flupirtine SCHEMBL25009 | 0.96 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL15357226 | 0.96 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL29400613 | 0.96 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL3896230 | 0.96 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505847 | 0.95 | KCNQ2 (0.98) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL28262990 | 0.95 | KCNQ2 (0.98) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505535 | 0.95 | KCNQ2 (0.98) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL1649863 | 0.94 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505446 | 0.94 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505680 | 0.94 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096163-A1 | Injectable dosage form of flupirtine | AWD.PHARMA GMBH & CO. KG (DE) | 2013-04-18 | — | — | US | claimed |
| EP-2579856-A1 | AN INJECTABLE DOSAGE FORM OF FLUPIRTINE | AWD.pharma GmbH & Co.KG (DE) | 2013-04-17 | — | — | EP | claimed |
| CN-103037848-A | An injectable dosage form of flupirtine | AWD PHARMA GMBH & CO KG | 2013-04-10 | — | — | CN | claimed |
| WO-2011157719-A1 | AN INJECTABLE DOSAGE FORM OF FLUPIRTINE | AWD.PHARMA GMBH & CO. KG (DE) | 2011-12-22 | — | — | WO | claimed |
| US-20130096163-A1 | Injectable dosage form of flupirtine | AWD.PHARMA GMBH & CO. KG (DE) | 2013-04-18 | — | — | US | disclosed |
| EP-2579856-A1 | AN INJECTABLE DOSAGE FORM OF FLUPIRTINE | AWD.pharma GmbH & Co.KG (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-20120028930-A1 | FLUPIRTINE SALTS AND POLYMORPHS | BIONEVIA PHARMACEUTICALS INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011157719-A1 | AN INJECTABLE DOSAGE FORM OF FLUPIRTINE | AWD.PHARMA GMBH & CO. KG (DE) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028930-A1 | FLUPIRTINE SALTS AND POLYMORPHS | SULT2A1, TACR1, NPSR1 | KCNQ2 1153/4885KCNQ3 1107/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.